Filing Details

Accession Number:
0001384101-20-000039
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-04 17:49:07
Reporting Period:
2020-03-03
Accepted Time:
2020-03-04 17:49:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1384101 Veracyte Inc. VCYT Services-Medical Laboratories (8071) 205455398
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1769333 C Giulia Kennedy 6000 Shoreline Court
Suite 300
South San Francisco CA 94080
Chief Scientific & Med Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-03 3,750 $6.45 102,872 No 4 M Direct
Common Stock Acquisiton 2020-03-03 1,563 $5.43 104,435 No 4 M Direct
Common Stock Acquisiton 2020-03-03 5,313 $9.05 109,748 No 4 M Direct
Common Stock Acquisiton 2020-03-03 4,407 $5.98 114,155 No 4 M Direct
Common Stock Disposition 2020-03-03 30,542 $25.35 83,613 No 4 S Direct
Common Stock Disposition 2020-03-03 2,339 $25.91 81,274 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-03-03 3,750 $6.45 3,750 $6.45
Common Stock Stock Option (right to buy) Disposition 2020-03-03 1,563 $5.43 1,563 $5.43
Common Stock Stock Option (right to buy) Disposition 2020-03-03 5,313 $9.05 5,313 $9.05
Common Stock Stock Option (right to buy) Disposition 2020-03-03 4,407 $5.98 4,407 $5.98
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2 2026-02-28 No 4 M Direct
522 2026-03-14 No 4 M Direct
21,250 2027-03-02 No 4 M Direct
35,250 2028-03-01 No 4 M Direct
Footnotes
  1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019.
  2. Represents weighted average sales price. Sale prices for the transactions range from $24.77 to $25.75. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  3. Represents weighted average sales price. Sale prices for the transactions range from $25.78 to $26.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
  4. The option is fully vested.
  5. The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
  6. The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
  7. The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.